Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05589961 | Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme | unknown | Early Phase 1 | 10 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05556382 | Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity(GEHIRN) | unknown | — | 30 | Istituto Clinico HumanitasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05515133 | Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma Patients | unknown | — | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05539339 | Personalized Trial in ctDNA-level-relapse Glioblastoma | unknown | N/A | 20 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05512195 | Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma(GBM) | unknown | N/A | 70 | Zhongnan HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT03722342 | TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma | unknown | Phase 1 | 9 | PharmAbcineINDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT02285959 | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | unknown | Phase 1 | 30 | Global Neurosciences InstituteOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05099068 | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)(PLANET) | unknown | N/A | 500 | Centre Leon BerardOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma(FUTURE-GB) | unknown | N/A | 357 | University of OxfordOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05033587 | Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 28 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03347097 | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme | unknown | Early Phase 1 | 40 | Huashan HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04970615 | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models(IMAGE-3D) | unknown | — | 60 | Sümeyye SezerOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04856852 | Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma(IBCNG) | unknown | N/A | 84 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Jun 29, 2021 | clinicaltrials |
| NCT04902586 | Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma(ECTG001) | unknown | N/A | 30 | Zhongnan HospitalOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT04874506 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | unknown | Phase 2 | 55 | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04829097 | Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma | unknown | Phase 3 | 80 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04772846 | Chloroquine for Glioblastoma. | unknown | Phase 1 / Phase 2 | 60 | Egyptian Medical SyndicateOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03258021 | TTFields In GErmany in Routine Clinical Care(TIGER) | unknown | — | 710 | NovoCure Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02904525 | Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model(XENOGBM) | unknown | N/A | 20 | Andreas HottingerOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04588454 | 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme(PSMA-GBM) | unknown | N/A | 5 | Radboud University Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04725214 | Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma | unknown | Phase 2 | 33 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04717999 | Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma | unknown | N/A | 20 | UWELL BiopharmaINDUSTRY | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04715620 | Niraparib Combined With Radiotherapy in rGBM | unknown | Phase 2 | 30 | Tianjin Huanhu HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04689087 | A Prospective, Open-label, Single-arm Clinical Study | unknown | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT04674527 | Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04674579 | Automatic Segmentation MRI Cerebral Glioma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04583020 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03903419 | Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients(PAraDiGM) | unknown | N/A | 16 | Centre Leon BerardOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03463733 | Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)(HUTMZ) | unknown | Phase 1 | 54 | M.E. van LindeOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04552977 | A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma | unknown | Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04547855 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | unknown | Phase 2 | 54 | Yonggao MouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01567202 | Study of DC Vaccination Against Glioblastoma | unknown | Phase 2 | 100 | Huashan HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04536649 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | unknown | Phase 3 | 369 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 31, 2022source: clinicaltrials